Study of affordability of pharmaceutical provision for type 2 diabetes therapy in Ukraine

Vlasenko, I.O. and Gladyshev, V.V. and Zaliska, О.M. and Davtian, L.L. (2025) Study of affordability of pharmaceutical provision for type 2 diabetes therapy in Ukraine. Медичні перспективи = Medicni perspektivi (Medical perspectives), ХХХ (2). pp. 247-254. ISSN 2307-0404 (print), 2786-4804 (online)

Text 247-254.pdf Download (589kB)

Abstract

Increasing the availability and affordability of medical and pharmaceutical care to the population is the most important task of all levels of government. The purpose of the work is to study the affordability of glucose-lowering drugs for the treatment of type 2 diabetes in Ukraine. Research materials are: State Register of Medicinal Products and price of glucose-lowering drugs. Marketing, analytical, graphic and pharmacoeconomic analysis were used. On the pharmaceutical market of Ukraine 161 glucose-lowering drugs are registered, which contain 16 international non-proprietary names and 8 international non-proprietary names combinations. It was established that the cost of Defined Daily Dose for mono glucose-lowering drugs varies from UAH 1,1 for glibenclamide up to UAH 90,7 for liraglutide. Most of the Ukrainian-made and foreign drugs are highly affordable, but foreign preparations of modern groups are moderately affordable, only one foreign drug, Liraglutide, is unaffordable ratio. But the analysis of affovailability for pensioners only metformin (Ukrainian production), glibenclamide, gliclazide, and glimepiride are highly affordable, three of which are already subject to reimbursement. Modern glucose-lowering drugs, both of foreign and Ukrainian production, is scarcely affordable, which makes it practically impossible to use them in the majority of retirees with diabetes. Thus, the analysis showed that in order to implement modern treatment schemes for type 2 diabetes, which according to the current legislation can be used in Ukraine, it is necessary to expand the list of glucose-lowering drugs included in the reimbursement program. This will improve treatment results, which in turn will reduce the development of diabetes complications and improve the quality of life of patients

Item Type:	Article
Additional Information:	DOI: 10.26641/2307-0404.2025.2.333711
Uncontrolled Keywords:	Key words: affordability, diabetes melitus, glucose-lowering drugs, reimbursement, solvency adequacy ratio, pharmacoeconomic research; доступність, цукровий діабет, цукрознижувальні препарати, відшкодування, коєфіцієнт адекватності платоспроможності, фармакоекономічні дослідженн
Subjects:	Social medicine Pharmacy
Divisions:	University periodicals > Medical perspectives
Depositing User:	Ирина Медведева
Date Deposited:	22 Apr 2026 10:22
Last Modified:	22 Apr 2026 10:22
URI:	http://repo.dma.dp.ua/id/eprint/9882

Actions (login required)

View Item